利福平与利福布汀对慢性肺曲霉病合并非结核分枝杆菌感染患者血清伊曲康唑水平的影响。
Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.
作者信息
Moon Seong Mi, Park Hye Yun, Jeong Byeong-Ho, Jeon Kyeongman, Lee Soo-Youn, Koh Won-Jung
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
出版信息
Antimicrob Agents Chemother. 2015 Jan;59(1):663-5. doi: 10.1128/AAC.04075-14. Epub 2014 Oct 13.
Abstract
We investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 μg/ml; P < 0.001) or rifabutin (median, 0.34 μg/ml; P < 0.001) than those receiving itraconazole alone (median, 5.92 μg/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections.
摘要
我们研究了利福平及利福布汀对慢性肺曲霉病患者血清伊曲康唑水平的影响。接受伊曲康唑联合利福平（中位数为0.1μg/ml；P<0.001）或联合利福布汀（中位数为0.34μg/ml；P<0.001）治疗的患者，其血清伊曲康唑浓度显著低于单独接受伊曲康唑治疗的患者（中位数为5.92μg/ml）。慢性肺曲霉病合并分枝杆菌感染的患者应避免同时使用利福平或利福布汀与伊曲康唑。
相似文献
1
Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.利福平与利福布汀对慢性肺曲霉病合并非结核分枝杆菌感染患者血清伊曲康唑水平的影响。
Antimicrob Agents Chemother. 2015 Jan;59(1):663-5. doi: 10.1128/AAC.04075-14. Epub 2014 Oct 13.
2
Effect of a 150 mg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease.150毫克剂量的利福布汀对合并慢性肺曲霉病和鸟分枝杆菌复合群肺病患者血清伊曲康唑水平的影响。
J Infect Chemother. 2017 Sep;23(9):658-660. doi: 10.1016/j.jiac.2017.02.004. Epub 2017 Mar 8.
3
Rifampin-resistant Mycobacterium kansasii infection in a patient with AIDS who was receiving rifabutin.
Clin Infect Dis. 1997 Jun;24(6):1262-3. doi: 10.1093/clinids/24.6.1262.
4
Update on rifampin, rifabutin, and rifapentine drug interactions.利福平、利福布汀和利福喷汀药物相互作用的最新进展。
Curr Med Res Opin. 2013 Jan;29(1):1-12. doi: 10.1185/03007995.2012.747952. Epub 2012 Nov 30.
5
Hyperpigmentation in a patient with AIDS, receiving rifabutin for disseminated Mycobacterium genavense infection.一名艾滋病患者在接受利福布汀治疗播散性日内瓦分枝杆菌感染时出现色素沉着。
Eur J Pediatr. 1998 Jul;157(7):612. doi: 10.1007/s004310050895.
6
Pulmonary Mycobacterium parascrofulaceum Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review.慢性进行性肺曲霉病患者并发副结核分枝杆菌肺部感染：一例报告及文献复习
Intern Med. 2020 Jun 1;59(11):1417-1422. doi: 10.2169/internalmedicine.3540-19. Epub 2019 Dec 20.
7
Tremor: a newly described adverse event with long-term itraconazole therapy.震颤：长期应用伊曲康唑治疗后新出现的不良反应。
J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):327-9. doi: 10.1136/jnnp.2009.174706.
8
Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis.非结核分枝杆菌肺部感染合并慢性坏死性肺曲霉病。
Thorax. 2000 Aug;55(8):717-9. doi: 10.1136/thorax.55.8.717.
9
Concomitant use of voriconazole and rifabutin in a patient with multiple infections.一名患有多种感染的患者同时使用伏立康唑和利福布汀。
Pharmacotherapy. 2008 Aug;28(8):1076-80. doi: 10.1592/phco.28.8.1076.
10
Nontuberculous mycobacterial pulmonary disease and co-infection: Bonnie and Clyde?非结核分枝杆菌肺病与合并感染：邦妮与克莱德？
Eur Respir J. 2019 Jul 4;54(1). doi: 10.1183/13993003.00117-2019. Print 2019 Jul.
引用本文的文献
1
The Effect of Rifapentine and Rifampicin on Serum Voriconazole Levels Persist for 5 Days and 7 Days or More After Discontinuation in Tuberculosis Patients with Chronic Pulmonary Aspergillosis.利福喷汀和利福平对慢性肺曲霉病合并结核病患者血清伏立康唑水平的影响在停药后持续5天及7天或更长时间。
Infect Drug Resist. 2024 Jul 8;17:2853-2862. doi: 10.2147/IDR.S461785. eCollection 2024.
2
Clinically important pharmacokinetic drug-drug interactions with antibacterial agents.具有临床重要意义的抗菌药物药代动力学药物相互作用。
Rev Esp Quimioter. 2024 Aug;37(4):299-322. doi: 10.37201/req/037.2024. Epub 2024 Jun 5.
3
Simultaneous diagnosis of allergic bronchopulmonary aspergillosis and complex lung disease.同时诊断变应性支气管肺曲霉病和复杂肺部疾病。
BMJ Case Rep. 2023 Sep 26;16(9):e255845. doi: 10.1136/bcr-2023-255845.
4
Lady Windermere syndrome with haemoptysis: suspected pulmonary aspergilloma and MAC pulmonary disease.肺曲霉菌病和 MAC 肺病：伴有咯血的肺静脉闭塞症/肺朗格汉斯组织细胞增生症。
BMJ Case Rep. 2023 Sep 15;16(9):e256349. doi: 10.1136/bcr-2023-256349.
5
Clinical Impact of Chronic Pulmonary Aspergillosis in Patients with Nontuberculous Mycobacterial Pulmonary Disease and Role of Computed Tomography in the Diagnosis.非结核分枝杆菌肺病患者中慢性肺部曲霉菌病的临床影响及计算机断层扫描在诊断中的作用。
Intern Med. 2023 Nov 15;62(22):3291-3298. doi: 10.2169/internalmedicine.0836-22. Epub 2023 Mar 15.
6
Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease.非结核分枝杆菌感染后的慢性肺曲霉病：一种新兴疾病。
J Fungi (Basel). 2020 Dec 8;6(4):346. doi: 10.3390/jof6040346.
7
A Case of Oral Histoplasmosis Concomitant with Pulmonary Tuberculosis.一例口腔组织胞浆菌病合并肺结核病例。
Case Rep Dent. 2019 Nov 3;2019:6895481. doi: 10.1155/2019/6895481. eCollection 2019.
8
Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?慢性肺曲霉病——我们现在何处？又将走向何方？
J Fungi (Basel). 2016 Jun 7;2(2):18. doi: 10.3390/jof2020018.
9
Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.非结核分枝杆菌肺病患者发生慢性肺曲霉病的危险因素。
PLoS One. 2017 Nov 30;12(11):e0188716. doi: 10.1371/journal.pone.0188716. eCollection 2017.
本文引用的文献
1
Chronic pulmonary aspergillosis: an update on diagnosis and treatment.慢性肺曲霉病：诊断与治疗的最新进展
Respiration. 2014;88(2):162-74. doi: 10.1159/000362674. Epub 2014 Jun 17.
2
Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis.非囊性纤维化支气管扩张症中的鸟分枝杆菌复合群感染
Respirology. 2014 Jul;19(5):714-22. doi: 10.1111/resp.12287. Epub 2014 Apr 1.
3
Chronic pulmonary aspergillosis.慢性肺曲霉病
Mycoses. 2014 May;57(5):257-70. doi: 10.1111/myc.12152. Epub 2013 Dec 2.
4
Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis.慢性肺曲霉病的临床特征和治疗结局。
Med Mycol. 2013 Nov;51(8):811-7. doi: 10.3109/13693786.2013.806826. Epub 2013 Jul 9.
5
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.从肺部样本中分离的非结核分枝杆菌的地理多样性：一项 NTM-NET 合作研究。
Eur Respir J. 2013 Dec;42(6):1604-13. doi: 10.1183/09031936.00149212. Epub 2013 Apr 18.
6
Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.伊曲康唑治疗慢性空洞性肺曲霉病：一项随机对照试验和文献系统评价。
Mycoses. 2013 Sep;56(5):559-70. doi: 10.1111/myc.12075. Epub 2013 Mar 18.
7
Update on rifampin, rifabutin, and rifapentine drug interactions.利福平、利福布汀和利福喷汀药物相互作用的最新进展。
Curr Med Res Opin. 2013 Jan;29(1):1-12. doi: 10.1185/03007995.2012.747952. Epub 2012 Nov 30.
8
Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease.分枝杆菌复合群肺病中区分鸟分枝杆菌和胞内分枝杆菌的临床意义。
Chest. 2012 Dec;142(6):1482-1488. doi: 10.1378/chest.12-0494.
9
Clinical characteristics and prognosis of chronic pulmonary aspergillosis.慢性肺曲霉病的临床特征和预后。
Respir Med. 2012 May;106(5):724-9. doi: 10.1016/j.rmed.2012.01.014. Epub 2012 Feb 19.
10
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis.慢性肺曲霉病作为肺结核的后遗症所带来的全球负担。
Bull World Health Organ. 2011 Dec 1;89(12):864-72. doi: 10.2471/BLT.11.089441. Epub 2011 Sep 27.
Zotero 插件